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L-carnitine is a beta-hydroxy carboxylic acid known as a dietary supplement with the effect of fat-burning or anti-
fatigue. Although several production processes of L-carnitine are proposed including fermentation, chiral 
resolution or asymmetric synthesis, there are disadvantages with each from the point of view of yield, side-
reactions or productivity. We have engaged in technology development of efficient enzymatic production of 
various chemicals for years, represented with the world’s first industrialized bioprocess for acrylamide. 
Leveraging our specialty including proprietary nitrile-related enzymes and associated technologies, we 





Halohydrin hydrogen-halide-lyase (H-lyase) is the enzyme capable of catalyzing the reversible dehalogenation 
of vicinal haloalcohols with formation of the corresponding epoxides (Figure 2). We envisioned the enzymatic 
process for L-carnitine production using HheB, a B-type H-lyase from Corynebacterium sp. N-1074, which can 
convert 1,3-dichloro-2-propanol (DCP) and hydrogen cyanide into 4-chloro-3-hydroxybutyronitrile (CHBN) with 
R-preference [1]. Although its unique feature and enantioselectivity were promising as the biocatalyst for our L-
carnitine process, its performance was not adequate from the point of view of industrial use. Thus, we attempted 




Regarding alleviation of  product-inhibition, we adopted a random approach. After screening over 20,000 
variants by evaluating activities in the presence of the product, that is (R)-CHBN, a few variants with alleviated 
inhibition were successfully obtained. Especially, D199H showed alleviated product inhibition not only by (R)-
CHBN but also by chloride ion, resulting in increased accumulation of  (R)-CHBN. As for enantioselectivity 
improvement, in contrast, a structure-based approach was conducted. The crystal structure of HheB led us to 
identify some key residues possibly affecting the enantioselectivity. Through saturation mutagenesis on focused 
residues, several variants with improved enantioselectivity were discovered. Among them, F71-variants showed 
remarkable improvement of enantioselectivity with increased accumulation of product, in spite of reduced initial 
activity.  Eventually, by combining those useful mutations, we succeeded in evolving wild-type HheB into the 
practical biocatalyst for L-carnitine production with industrial-level performance [2, 3]. 
 
References 
[1] Tetrahedron, 50 (41), 11821-11826 (1994). 
[2] Patent WO/2008/108466 
[3] J. Biosci. Bioeng., 122 (3), 270-275 (2016) 
Figure 1 – L-carnitine enzymatic production process 
Figure 2 – Reaction catalyzed by H-lyase 
